Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC25A53 pseudogene 1 (SLC25A53P1) is classified as a pseudogene and not a protein-coding gene or functional therapeutic target. Genuine members of the SLC25A53 family are predicted to enable NAD transmembrane transporter activity and reside within the mitochondria[3], but pseudogenes like SLC25A53P1 generally do not encode functional proteins and are not implicated as disease targets or direct biomarkers. There is no established molecular function, disease association, or pharmacological relevance for SLC25A53P1 in the scientific literature. Note: There is no evidence supporting SLC25A53P1 as a therapeutic target, nor information about its biological function, interacting drugs, or clinical significance; if a functional target is required, refer instead to SLC25A53 (Solute carrier family 25 member 53)[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLC25A53 pseudogene 1 (SLC25A53P1).